Home > Oncology > ASCO 2020 > Lung Cancer > MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib

MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib

Presented By
Prof. Jürgen Wolf, University Hospital Cologne, Germany
Conference
ASCO 2020
Trial
Phase 2, GEOMETRY
MET mutations and MET amplifications are reported in 1-6% of patients with non–small cell lung cancer (NSCLC). In the ongoing, multicohort phase 2 GEOMETRY trial, patients with stage III/IV NSCLC and high-level MET amplification (gene copy number >10) responded well to capmatinib, a highly potent and selective inhibitor of the MET receptor tyrosine kinase. In the GEOMETRY trial, 84 patients with high-level MET amplification (ALK and EGFR wildtype, stage IIIB/IV) received capmatinib 400 mg twice daily (n=15 were treatment-naïve, n=69 were second or third line). The primary endpoint of the trial was the objective response rate (ORR), while secondary endpoints were duration of response (DOR), progression-free survival (PFS), and overall survival (OS). “The ORR in the treatment-naïve patients was 40%, and 29% in the pre-treated patients”, reported Prof. Jürgen Wolf (University Hos...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on